1-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-methylpiperidine-4-carboxamide → 5-(6-((1-Methylpiperidin-4-yl-n-methylamino)methyl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-2-yl)pyrimidin-2-amine

Participants

Role	Name	HCID	Charge
Reactant	1-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-methylpiperidine-4-carboxamide	HCID 58233852	—
Reactant	N-((2-chloro-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,1-dimethylpiperidin-4-amine	HCID 86623525	—
Product	5-(6-((1-Methylpiperidin-4-yl-n-methylamino)methyl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-2-yl)pyrimidin-2-amine	HCID 58234071	5%

Reaction Steps

N-((2-chloro-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,1-dimethylpiperidin-4-amine following Example 115 (0.23 mmol) was reacted using General Procedure A: Suzuki Coupling to give 190 (TFA salt) in a 5% yield after reverse-phase HPLC purification. MS (Q1) 469 (M)+.

Provenance & Evidence

DOI	10.6084/m9.figshare.5104873.v1
Patent number	US08383620B2
Source dataset	uspto-grants-2013_02
ORD ID	ord-1a9cedec07cf452db26fe2591beaa7db
Source note	uspto-grants-2013_02